Novel γ-secretase modulators: a review of patents from 2008 to 2010

Bibliography

• Bergmans BA, De Strooper B. gamma-Secretases: from cell biology to therapeutic strategies. Lancet Neurol 2010;9:215-26
   PubMedGoogle Scholar
• Selkoe DJ, Wolfe MS. Presenilin: running with scissors in the membrane. Cell 2007;131:215-21
   PubMed Web of Science ®Google Scholar
• Wolfe MS. The gamma-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry 2006;45:7931-9
   PubMed Web of Science ®Google Scholar
• Ahn K, Shelton CC, Tian Y, Activation and intrinsic gamma-secretase activity of presenilin 1. Proc Natl Acad Sci USA 2010 doi: 10.1073/pnas.1013246107
   Google Scholar
• Li YM, Xu M, Lai MT, Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 2000;405:689-94
   PubMed Web of Science ®Google Scholar
• Esler WP, Kimberly WT, Ostaszewski BL, Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat Cell Biol 2000;2:428-34
   PubMed Web of Science ®Google Scholar
• Beel AJ, Sanders CR. Substrate specificity of gamma-secretase and other intramembrane proteases. Cell Mol Life Sci 2008;65:1311-34
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-6
   PubMed Web of Science ®Google Scholar
• Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005;120:545-55
   PubMed Web of Science ®Google Scholar
• Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron 2010;68:270-81
   PubMed Web of Science ®Google Scholar
• Fleisher AS, Raman R, Siemers ER, Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008;65:1031-8
   PubMed Web of Science ®Google Scholar
• Bateman RJ, Siemers ER, Mawuenyega KG, A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 2009;66:48-54
   PubMed Web of Science ®Google Scholar
• Extance A. Alzheimer's failure raises questions about disease-modifying strategies. Nat Rev Drug Discov 2010;9:749-51
   PubMed Web of Science ®Google Scholar
• De Strooper B, Annaert W, Cupers P, A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999;398:518-22
   PubMed Web of Science ®Google Scholar
• Wong GT, Manfra D, Poulet FM, Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004;279:12876-82
   PubMed Web of Science ®Google Scholar
• van Es JH, van Gijn ME, Riccio O, Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005;435:959-63
   PubMed Web of Science ®Google Scholar
• Costa RM, Drew C, Silva AJ. Notch to remember. Trends Neurosci 2005;28:429-35
   PubMed Web of Science ®Google Scholar
• Louvi A, Artavanis-Tsakonas S. Notch signalling in vertebrate neural development. Nat Rev Neurosci 2006;7:93-102
   PubMed Web of Science ®Google Scholar
• Gillman KW, Starrett JE, Parker MF, Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable gamma-secretase inhibitor. ACS Med Chem Lett 2010;1:120-4
   PubMed Web of Science ®Google Scholar
• Kreft AF, Martone R, Porte A. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease. J Med Chem 2009;52:6169-88
   PubMed Web of Science ®Google Scholar
• Weggen S, Eriksen JL, Das P, A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001;414:212-16
   PubMed Web of Science ®Google Scholar
• Eriksen JL, Sagi SA, Smith TE, NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 2003;112:440-9
   PubMed Web of Science ®Google Scholar
• Weggen S, Eriksen JL, Sagi SA, Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem 2003;278:31831-7
   PubMed Web of Science ®Google Scholar
• Peretto I, Radaelli S, Parini C, Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1-42) secretion. J Med Chem 2005;48:5705-20
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Black SE, Hendrix SB, Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 2008;7:483-93
   PubMed Web of Science ®Google Scholar
• Imbimbo BP. Why did tarenflurbil fail in Alzheimer's disease? J Alzheimers Dis 2009;17:757-60
   PubMed Web of Science ®Google Scholar
• Imbimbo BP, Del Giudice E, Colavito D, 1-(3′,4′-Dichloro-2-fluoro[1,1′-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J Pharmacol Exp Ther 2007;323:822-30
   PubMed Web of Science ®Google Scholar
• Safety, pharmacokinetics and pharmacodynamics study of treatment with CHF5074 in healthy young male subjects. Available from: www.clinicaltrials.gov/ct2/show/NCT00954252?term=CHF5074&rank=2 [Last accessed 29 October 2010]
   Google Scholar
• Takahashi Y, Hayashi I, Tominari Y, Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J Biol Chem 2003;278:18664-70
   PubMed Web of Science ®Google Scholar
• Beher D, Clarke EE, Wrigley JD, Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J Biol Chem 2004;279:43419-26
   PubMed Web of Science ®Google Scholar
• Zettl H, Weggen S, Schneider P, Exploring the chemical space of gamma-secretase modulators. Trends Pharmacol Sci 2010;31:402-10
   PubMed Web of Science ®Google Scholar
• Kukar TL, Ladd TB, Bann MA, Substrate-targeting gamma-secretase modulators. Nature 2008;453:925-9
   PubMed Web of Science ®Google Scholar
• Beel AJ, Barrett P, Schnier PD, Nonspecificity of binding of gamma-secretase modulators to the amyloid precursor protein. Biochemistry 2009;48:11837-9
   PubMedGoogle Scholar
• Page RM, Gutsmiedl A, Fukumori A, Beta-amyloid precursor protein mutants respond to gamma-secretase modulators. J Biol Chem 2010;285:17798-810
   PubMedGoogle Scholar
• Okochi M, Fukumori A, Jiang J, Secretion of the Notch-1 Abeta-like peptide during Notch signaling. J Biol Chem 2006;281:7890-8
   PubMedGoogle Scholar
• Richter L, Munter LM, Ness J, Amyloid beta 42 peptide-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization. Proc Natl Acad Sci USA 2010;107:14597-602
   PubMed Web of Science ®Google Scholar
• Lleo A, Berezovska O, Herl L, Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med 2004;10:1065-6
   PubMed Web of Science ®Google Scholar
• Uemura K, Farner KC, Hashimoto T, Substrate docking to gamma-secretase allows access of gamma-secretase modulators to an allosteric site. Nat Commun 2010;1:130
   PubMed Web of Science ®Google Scholar
• Neurogenetics, Inc. WO04110350; 2004
   Google Scholar
• Eisai Co., Ltd. WO05115990; 2005
   Google Scholar
• Hashimoto T, Ishibashi A, Hagiwara H, E2012: a novel gamma-secretase modulator -pharmacology part [abstract P1-236]. 13th Int Conf Alzheimer's Dis Relat Disord (ICAD); 10 – 15 July 2010; Honolulu
   Google Scholar
• Recruiting a randomized, double-blind, placebo-controlled, sequential ascending, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of E2212 in healthy subjects. Available from: www.clinicaltrials.gov/ct2/results?term=E2212 [Last accessed 29 October 2010]
   Google Scholar
• Portelius E, Van Broeck B, Andreasson U, Acute effect on the Abeta isoform pattern in CSF in response to gamma-secretase modulator and inhibitor treatment in dogs. J Alzheimers Dis 2010;21:1005-12
   PubMed Web of Science ®Google Scholar
• Kounnas MZ, Danks AM, Cheng S, Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 2010;67:769-80
   PubMed Web of Science ®Google Scholar
• Garofalo AW. Patents targeting gamma-secretase inhibition and modulation for the treatment of Alzheimer's disease: 2004-2008. Expert Opin Ther Pat 2008;18:693-703
   Web of Science ®Google Scholar
• Hattori K, Wakabayashi H, Tamaki K. Predicting key example compounds in competitors' patent applications using structural information alone. J Chem Inf Model 2008;48:135-42
   PubMed Web of Science ®Google Scholar
• Myriad Genetics, Inc. US080249135; 2008
   Google Scholar
• Merck & Co., Inc. WO08085301; 2008
   Google Scholar
• Stanton MG, Hubbs J, Sloman D, Fluorinated piperidine acetic acids as gamma-secretase modulators. Bioorg Med Chem Lett 2010;20:755-8
   PubMedGoogle Scholar
• Hall A, Elliott RL, Giblin GM, Piperidine-derived gamma-secretase modulators. Bioorg Med Chem Lett 2010;20:1306-11
   PubMed Web of Science ®Google Scholar
• EnVivo Pharmaceuticals, Inc. WO09036428; 2009
   Google Scholar
• EnVivo Pharmaceuticals, Inc. WO09086277; 2009
   Google Scholar
• Janssen Pharmaceutica, N.V. WO09051948; 2009
   Google Scholar
• Janssen Pharmaceutica, N.V. WO09052079; 2009
   Google Scholar
• Janssen Pharmaceutica, N.V. WO09052126; 2009
   Google Scholar
• Janssen Pharmaceutica, N.V. WO09052334; 2009
   Google Scholar
• Janssen Pharmaceutica, N.V. WO09052350; 2009
   Google Scholar
• Janssen Pharmaceutica, N.V. WO10011626; 2010
   Google Scholar
• Eisai Co., Ltd. US060004013; 2006
   Google Scholar
• Eisai Co., Ltd. WO06046575; 2006
   Google Scholar
• Eisai R&D Management Co., Ltd. WO07058305; 2007
   Google Scholar
• Eisai R&D Management Co., Ltd. WO08140111; 2008
   Google Scholar
• Eisai R&D Management Co., Ltd. WO07058304; 2007
   Google Scholar
• Imbimbo BP. Alzheimer's disease: gamma-secretase inhibitors. Drug Discov Today Ther Strateg 2008;5:169-75
   Google Scholar
• Imbimbo BP. Therapeutic potential of gamma-secretase inhibitors and modulators. Curr Top Med Chem 2008;8:54-61
   PubMed Web of Science ®Google Scholar
• FY2009 Product Creation Meeting, 18 December 2009, Eisai Co., Ltd. Available from: www.eisai.co.jp/pdf/eir/emat/material20091218e.pdf, [Last accessed 23 October 2010]
   Google Scholar
• Eisai R&D Management Co., Ltd. US070117839; 2007
   Google Scholar
• Eisai R&D Management Co., Ltd. US070117798; 2007
   Google Scholar
• Eisai R&D Management Co., Ltd. US080207900; 2008
   Google Scholar
• Eisai R&D Management Co., Ltd. WO07102580; 2007
   Google Scholar
• Eisai R&D Management Co., Ltd. WO09028588; 2009
   Google Scholar
• Eisai R&D Management Co., Ltd. US090062529; 2009
   Google Scholar
• Eisai R&D Management Co., Ltd. WO10025197; 2010
   Google Scholar
• Eisai R&D Management Co., Ltd. WO10098496; 2010
   Google Scholar
• Eisai R&D Management Co., Ltd. WO10098332; 2010
   Google Scholar
• Eisai R&D Management Co., Ltd. WO10098490; 2010
   Google Scholar
• Eisai R&D Management Co., Ltd. WO10098495; 2010
   Google Scholar
• Calculated using clogP v4.3. (2008) BioByte Software, BioByte Corporation, Claremont, CA
   Google Scholar
• Merck & Co., Inc. WO08097538; 2008
   Google Scholar
• Schering Corp. WO09005729; 2009
   Google Scholar
• Schering Corp. WO09045314; 2009
   Google Scholar
• Schering Corp. WO09020580; 2009
   Google Scholar
• Schering Corp. WO08153792; 2008
   Google Scholar
• Schering Corp. WO08153793; 2008
   Google Scholar
• Schering Corp. WO10054067; 2010
   Google Scholar
• Schering Corp. WO08137139; 2008
   Google Scholar
• Schering Corp. WO10054078; 2010
   Google Scholar
• Schering Corp. WO10054064; 2010
   Google Scholar
• Schering Corp. WO09061699; 2009
   Google Scholar
• Caldwell JP, Bennett CE, McCracken TM, Iminoheterocycles as gamma-secretase modulators. Bioorg Med Chem Lett 2010;20:5380-4
   PubMedGoogle Scholar
• Zhu Z, Sun ZY, Ye Y, Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: part I–inhibitor design and validation. J Med Chem 2010;53:951-65
   PubMed Web of Science ®Google Scholar
• Dosed orally at 10 mg/kg. Brain concentration at 6 h for 35 and 37 were 914 and 275 ng/g, respectively
   Google Scholar
• Schering Corp. WO10075203; 2010
   Google Scholar
• Schering Corp. WO10075204; 2010
   Google Scholar
• Schering Corp. WO09108766; 2009
   Google Scholar
• Schering Corp. WO09032277; 2009
   Google Scholar
• Huang X, Aslanian R, Zhou W, The discovery of pyridone and pyridazone heterocycles as gamma-secretase modulators. ACS Med Chem Lett 2010;1:184-7
   PubMed Web of Science ®Google Scholar
• Schering Corp. WO09076337; 2009
   Google Scholar
• Schering Corp. US100137320; 2010
   Google Scholar
• Schering Corp. WO09076352; 2009
   Google Scholar
• Schering Corp. WO09073779; 2009
   Google Scholar
• Merck & Co., Inc. WO08156580; 2008
   Google Scholar
• Merck & Co., Inc. WO10071741; 2010
   Google Scholar
• Merck & Co., Inc. WO10077582; 2010
   Google Scholar
• Eisai R&D Management Co., Ltd. WO10098488; 2010
   Google Scholar
• Glaxo Group Ltd. WO09050227; 2009
   Google Scholar
• Hoffmann-La Roche, Inc. US080280948; 2008
   Google Scholar
• Hoffmann-La Roche, Inc. WO09087127; 2009
   Google Scholar
• Hoffmann-La Roche, Inc. WO09103652; 2009
   Google Scholar
• Hoffmann-La Roche, Inc. WO10040661; 2010
   Google Scholar
• Hoffmann-La Roche, Inc. WO10052199; 2010
   Google Scholar
• AstraZeneca AB. WO10053438; 2010
   Google Scholar
• Ortho-McNeil-Janssen Pharmaceuticals, Inc. WO10070008; 2010
   Google Scholar
• Ortho-McNeil-Janssen Pharmaceuticals, Inc. WO10089292; 2010
   Google Scholar
• Ortho-McNeil-Janssen Pharmaceuticals, Inc. WO10094647; 2010
   Google Scholar
• Bristol-Myers Squibb Co. WO10083141; 2010
   Google Scholar
• Eisai R&D Management Co., Ltd. WO07135969; 2007
   Google Scholar
• TorreyPines Therapeutics, Inc. WO08137102; 2008
   Google Scholar
• Amgen, Inc. WO09137404; 2009
   Google Scholar
• Amgen, Inc. WO09075874; 2009
   Google Scholar
• Pfizer, Inc. WO10100606; 2010
   Google Scholar
• Merck & Co., Inc. WO08100412; 2008
   Google Scholar
• Merck & Co., Inc. WO08099210; 2008
   Google Scholar
• Merck & Co., Inc. WO10019392; 2010
   Google Scholar
• Merck & Co., Inc. WO10019393; 2010
   Google Scholar
• Rivkin A, Ahearn SP, Chichetti SM, Piperazinyl pyrimidine derivatives as potent gamma-secretase modulators. Bioorg Med Chem Lett 2010;20:1269-71
   PubMedGoogle Scholar
• Rivkin A, Ahearn SP, Chichetti SM, Purine derivatives as potent gamma-secretase modulators. Bioorg Med Chem Lett 2010;20:2279-82
   PubMedGoogle Scholar
• Wager TT, Ramalakshmi YC, Hou X, Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem Neurosci 2010;1:420-35
   PubMed Web of Science ®Google Scholar
• Morphy R. The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. J Med Chem 2006;49:2969-78
   PubMed Web of Science ®Google Scholar
• Hughes JD, Blagg J, Price DA, Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 2008;18:4872-5
   PubMed Web of Science ®Google Scholar